| Reaction Details |
|---|
 | Report a problem with these data |
| Target | 5-hydroxytryptamine receptor 1A |
|---|
| Ligand | BDBM50033852 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_917 (CHEMBL615765) |
|---|
| Ki | 0.08±n/a nM |
|---|
| Citation |  Perrone, R; Berardi, F; Colabufo, NA; Leopoldo, M; Lacivita, E; Tortorella, V; Leonardi, A; Poggesi, E; Testa, R trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines. J Med Chem44:4431-42 (2001) [PubMed] |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| 5-hydroxytryptamine receptor 1A |
|---|
| Name: | 5-hydroxytryptamine receptor 1A |
|---|
| Synonyms: | 5-HT-1A | 5-HT1A | 5-hydroxytryptamine receptor 1A (5-HT-1A) | 5HT1A_HUMAN | ADRB2RL1 | ADRBRL1 | Dopamine D2 receptor and serotonin 1a receptor | G-21 | HTR1A | Serotonin receptor 1A |
|---|
| Type: | n/a |
|---|
| Mol. Mass.: | 46122.49 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | n/a |
|---|
| Residue: | 422 |
|---|
| Sequence: | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ
|
|
|
|---|
| BDBM50033852 |
|---|
| n/a |
|---|
| Name | BDBM50033852 |
|---|
| Synonyms: | 1-[3-(5-Methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-4-pyridin-2-yl-piperazine | CHEMBL444590 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C23H31N3O |
|---|
| Mol. Mass. | 365.5117 |
|---|
| SMILES | COc1cccc2C(CCCN3CCN(CC3)c3ccccn3)CCCc12 |
|---|
| Structure | 
|
|---|
Search and Browse
